San Diego, California
United States
96
2026-06-18
The entities that hold a legal rights for patent applications filed by inventor Davis Robert:
Robert Davis from San Diego, US has applied for patents for these inventions. The list has both pending applications and granted patents:
METHODS OF TREATING DEPRESSION AND ANXIETY
#2 | 2026-02-12ORGANIC COMPOUNDS
#3 | 2025-11-27NOVEL METHODS
#4 | 2025-11-06ORGANIC COMPOUNDS
#5 | 2025-10-09METHODS OF TREATING NEUROPATHIC PAIN
#6 | 2025-09-04TRANSMUCOSAL METHODS FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS
#7 | 2025-07-31ORGANIC COMPOUNDS
#8 | 2025-06-19ORGANIC COMPOUNDS
#9 | 2025-04-24METHODS OF TREATING ACUTE DEPRESSION AND ANXIETY
#10 | 2025-01-09NOVEL COMPOSITIONS AND METHODS
#11 | 2024-11-14NOVEL METHODS
#12 | 2024-09-19NOVEL METHODS
#13 | 2024-08-01NOVEL METHODS
#14 | 2024-07-25NOVEL METHODS
#15 | 2024-07-04Pharmaceutical capsules comprising lumateperone mono-tosylate
#16 | 2024-06-27NOVEL COMPOUNDS AND METHODS
#17 | 2024-06-27NOVEL METHODS
#18 | 2024-05-23ORGANIC COMPOUNDS
#19 | 2024-03-21NOVEL USES
#20 | 2024-03-21Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
#21 | 2024-02-29Methods
#22 | 2024-02-22Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs
#23 | 2024-02-01NOVEL METHODS
#24 | 2024-01-25NOVEL METHODS
#25 | 2024-01-18TRANSMUCOSAL METHODS FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS
#26 | 2024-01-11NOVEL USES
#27 | 2023-11-09METHODS OF TREATMENT
#28 | 2023-10-26Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one for treating central nervous system disorders
#29 | 2023-10-26NOVEL USES
#30 | 2023-09-28Transmucosal methods for treating psychiatric and neurological conditions
#31 | 2023-08-31Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-ol for treating central nervous system disorders
#32 | 2023-06-29Organic compounds
#33 | 2023-06-15Organic compounds
#34 | 2022-11-24Organic compounds
#35 | 2022-11-10NOVEL COMPOUNDS
#36 | 2022-11-10METHODS OF TREATMENT
#37 | 2022-09-22ORGANIC COMPOUNDS
#38 | 2022-06-16ORGANIC COMPOUNDS
#39 | 2022-06-16METHODS OF TREATING NEUROPATHIC PAIN
#40 | 2022-05-12Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate
#41 | 2022-04-28NOVEL DEVICES
#42 | 2022-03-24METHODS OF TREATING ADDICTION
#43 | 2022-03-10ORGANIC COMPOUNDS
#44 | 2022-03-10ORGANIC COMPOUNDS
#45 | 2022-02-24Organic compounds
#46 | 2022-02-24Organic compound
#47 | 2021-12-02Compounds and methods
#48 | 2021-11-25Transmucosal methods for treating psychiatric and neurological conditions
#49 | 2021-10-21NOVEL METHODS
#50 | 2021-10-14Compositions and methods
#51 | 2021-09-30Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
#52 | 2021-07-22Methods
#53 | 2021-07-08ORGANIC COMPOUNDS
#54 | 2021-07-08Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine Asignaling and/or adenosine Areceptor expression
#55 | 2021-06-24Organic compounds
#56 | 2021-06-03Organic compounds
#57 | 2021-05-20Organic compounds
#58 | 2021-04-01Methods
#59 | 2021-03-04ORGANIC COMPOUNDS
#60 | 2021-03-04Methods of treating acute depression and/or acute anxiety
#61 | 2021-02-04Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system
#62 | 2021-01-14ORGANIC COMPOUNDS
#63 | 2021-01-14ORGANIC COMPOUNDS
#64 | 2021-01-07NOVEL METHODS
#65 | 2021-01-07NOVEL METHODS
#66 | 2020-12-31NOVEL METHODS
#67 | 2020-12-03Transmucosal methods for treating psychiatric and neurological conditions
#68 | 2020-10-01Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
#69 | 2020-09-17Uses
#70 | 2020-09-10Amplified ballistic separator for separating material
#71 | 2020-08-06Organic compounds
#72 | 2020-05-05Amplified ballistic separator for separating material
#73 | 2020-04-02Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system
#74 | 2020-03-05Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
#75 | 2020-01-16Compositions and methods
#76 | 2019-11-14Organic compounds
#77 | 2019-10-31Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
#78 | 2019-10-31Methods of treating bipolar disorder
#79 | 2019-10-03Pharmaceutical compositions for sustained or delayed release
#80 | 2019-09-26Methods of treating schizophrenia and depression
#81 | 2019-06-13Organic compounds
#82 | 2019-03-07Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activity
#83 | 2019-02-28Organic compounds
#84 | 2018-09-27Transmucosal and subcutaneous compositions
#85 | 2018-07-19Methods
#86 | 2017-11-09Organic compounds
#87 | 2017-10-05Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
#88 | 2017-06-29Organic compounds
#89 | 2017-04-27Compounds and methods of use to treat schizophrenia
#90 | 2017-02-09Organic compounds
#91 | 2016-10-27Method for the treatment of residual symptoms of schizophrenia
#92 | 2016-05-26Free base crystals
#93 | 2015-06-18Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
#94 | 2013-12-26Disc for disc screen
#95 | 2013-11-07Multi-disc assembly for disc screen
#96 | 2011-12-22PDE1 inhibitors for ophthalmic disorders
514380 ⎘